ACXP — Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 4
- Website: https://www.acurxpharma.com
Latest SEC filings for ACXP
- ARS — 2026-09-01
- 10-Q — 2026-08-13
- EFFECT — 2026-05-12
- EFFECT — 2026-05-12
- 424B3 — 2026-05-12
- 424B3 — 2026-05-12
- 10-Q — 2026-05-11
- S-1 — 2026-05-04
- S-1 — 2026-05-04
- S-1 — 2026-05-04
Latest ACXP news
- — Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection (prnewswire.com)
Educational tool only — not investment advice.